AVROBIO
One Kendall Square
Building 300, Suite 201
Cambridge
MA
02139
United States
Tel: 617.914.8420
Website: https://avrobio.com/
Email: info@AVROBIO.com
About AVROBIO
AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. The Company is focused on the development of its gene therapy candidate, AVR RD 01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. AVROBIO’s lentiviral platform has broad potential for other rare and non-rare genetic diseases.
We are headquartered in Cambridge, MA and have offices in Toronto, ON. Please visit our website www.avrobio.com for more information on who we are, what we care about and how we are bringing these therapies to our patients.
160 articles about AVROBIO
-
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 06, 2022
4/6/2022
AVROBIO, Inc. announced that the company has granted a non-statutory stock option for the purchase of up to 22,000 shares of the company’s common stock to one employee as an inducement award under the company’s 2019 Inducement Plan.
-
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference
4/5/2022
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference.
-
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
3/17/2022
AVROBIO, Inc. today reported financial results for the fourth quarter and year ended Dec. 31, 2021, and provided a business update.
-
AVROBIO to Present at Two Upcoming Investor Conferences in March
3/1/2022
AVROBIO to Present at Two Upcoming Investor Conferences in March.
-
AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis
2/9/2022
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported interim data from a collaborator-sponsored, ongoing Phase 1/2 clinical trial of AVR-RD-04.
-
AVROBIO Announces Today Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/4/2022
AVROBIO, Inc. today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 167,000 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan.
-
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
2/1/2022
AVROBIO, Inc. today announced the appointment of Sean O’Bryan as chief regulatory officer.
-
AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit
1/28/2022
AVROBIO, Inc. announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO, will present virtually at Cowen’s 2nd Annual Genetic Medicines Summit at 2:00 p.m. ET on Thursday, Feb. 3, 2022.
-
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
1/27/2022
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposium™ in San Diego, Calif.
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 06, 2022
1/6/2022
AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 30,500 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan.
-
AVROBIO Reprioritizes Pipeline Programs
1/4/2022
AVROBIO, Inc. today announced that it is shifting its portfolio priorities to focus on other clinical-stage programs and extending its cash runway into the first quarter of 2024.
-
AVROBIO is switching priorities in 2022 away from its Fabry disease program and into its other more lucrative clinical-stage projects.
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 07, 2021
12/7/2021
AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 14,500 shares of the company’s common stock to two new employees as inducement awards under the company’s 2019 Inducement Plan.
-
AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1
11/24/2021
AVROBIO, Inc. today hosted a panel of investigators managing the patient experience in the Phase 2 FAB-GT clinical trial of AVR-RD-01, an investigational one-time gene therapy for Fabry disease, at the 14th International Congress of Inborn Errors of Metabolism (ICIEM), Nov. 21-23, 2021, in Sydney, Australia.
-
Avrobio’s ex vivo lentiviral gene therapy platform led to durable responses measured in years, and significant reductions in disease-related biomarkers that far exceed today’s standard of care.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
11/8/2021
AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
-
AVROBIO Announced Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/5/2021
AVROBIO, Inc. today announced that the company has granted a non-statutory stock option for the purchase of up to 120,000 shares of the company’s common stock to the company’s new Chief Medical Officer, Essra Ridha, M.D., as an inducement award under the company’s 2019 Inducement Plan.
-
AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
11/4/2021
AVROBIO, Inc. today reported financial results for the quarter ended Sept. 30, 2021, and provided a business update.
-
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
11/3/2021
AVROBIO, Inc today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to AVR-RD-05, its lentiviral gene therapy for the treatment of mucopolysaccharidosis type II (MPSII), or Hunter syndrome